论文部分内容阅读
目的:观察丝裂霉素C在激光泪道成形术中的临床疗效。方法:泪道阻塞患者118例(162眼)随机分为2组,对照组58例(80眼)在激光泪道成形术后,将妥布霉素/地塞米松眼膏注入泪道,试验组60例(82眼)在激光泪道成形术后将0.2g·L-1丝裂霉素C溶液注入泪道并停留5min后,将妥布霉素/地塞米松眼膏注入泪道。观察2组的泪道是否通畅及有无丝裂霉素C的不良反应。结果:术后随访6～12个月,试验组与对照组的总有效率分别为91.5%、80.0%,差异有统计学意义(χ2=4.37,P<0.05)。随访中未发现丝裂霉素C的并发症。结论:在激光泪道成形术中,0.2g·L-1丝裂霉素C的应用是安全的,可提高手术的成功率。
Objective: To observe the clinical efficacy of mitomycin C in laser lacrimaloplasty. Methods: 118 patients (162 eyes) with lacrimal duct obstruction were randomly divided into two groups. In control group, 58 eyes (80 eyes) were injected with tobramycin / dexamethasone ointment into lacrimal passage after laser lacrimal ductoplasty. Group 60 (82 eyes) After laser lacrimal duct surgery 0.2g · L-1 mitomycin C solution into the lacrimal duct and stay 5min, the tobramycin / dexamethasone ointment into the lacrimal duct. Observe group 2 lacrimal duct patency and with or without mitomycin C adverse reactions. Results: The total effective rates of the experimental group and the control group were 91.5% and 80.0%, respectively, with a statistically significant difference (χ2 = 4.37, P <0.05) after 6 to 12 months of follow-up. No complications of mitomycin C were found during follow-up. Conclusion: The application of 0.2g · L-1 mitomycin C in laser lacrimaloplasty is safe and can improve the success rate of surgery.